Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized.
PHATHOM PHARMACEUTICALS, INC.
/s/ Terrie Curran
Terrie CurranChief Executive Officer
Date: March 6, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Terrie CurranTerrie Curran | President, Chief Executive Officer andDirector (Principal Executive Officer) | March 6, 2025 |
| /s/ Molly HendersonMolly Henderson | Chief Financial and Business Officer (Principal Financial and Accounting Officer) | March 6, 2025 |
| *Michael F. Cola | Director | March 6, 2025 |
| *Frank Karbe | Director | March 6, 2025 |
| *Heidi Kunz | Director | March 6, 2025 |
| *Asit Parikh, M.D., Ph.D. | Director | March 6, 2025 |
| *David Socks | Director | March 6, 2025 |
| *Mark Stenhouse | Director | March 6, 2025 |
| *James Topper, M.D., Ph.D. | Director | March 6, 2025 |
*By:/s/ Terrie Curran
Terrie Curran, Attorney-in-fact
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.